Maternal serum placental growth hormone and insulinlike growth factor binding proteins 1 and 3 in pregnancies affected by fetal aneuploidy and other abnormalities: Implications for prenatal diagnosis of trisomy 21
S. Moghadam et al., Maternal serum placental growth hormone and insulinlike growth factor binding proteins 1 and 3 in pregnancies affected by fetal aneuploidy and other abnormalities: Implications for prenatal diagnosis of trisomy 21, FETAL DIAGN, 13(5), 1998, pp. 291-297
In the present study, we determined circulating serum levels of human place
ntal growth hormone (hPGH) and insulinlike growth factor binding proteins 1
and 3 (IGFBP-1 and IGFBP-3) using two-site radioimmunoassays during the ge
stational midtrimester of pregnancies affected by chromosomal disorders wit
h the aim of identifying potential marker substances that might have a sign
ificant discriminative and predictive value for prenatal diagnosis of fetal
chromosomal aberrations and of organ malformations such as neural-tube def
ect. Our results show that the maternal serum levels of hPGH were significa
ntly elevated in pregnancies affected by chromosomal anomalies or organ mal
formations as compared with controls. The distribution of IGFBP-1 concentra
tions for all experimental groups except trisomy 21 were closely similar to
the normal population. IGFBP-3 decreased slightly in pregnancies affected
by Down syndrome. These findings suggest that hPGH may be useful as an addi
tional marker in prenatal screening for Down syndrome.